摘要
目的:观察羟基喜树碱(HCPT)联合卡铂(CBP)组成的HC方案治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:40例ⅢB～Ⅳ期NSCLC患者,年龄70～82岁,应用HC方案化疗,即HCPT6mg/m2ivgttd1～d5,CBP(AUC=5)ivgttd1,q21～28d。依据WHO标准评价近期客观疗效及其毒性,并且观察QOL和KPS评分变化情况。结果:全组40例患者中,有38例可以评价疗效,获得PR16例,SD14例,PD8例,RR(CR+PR)为42.1%,DCR(CR+PR+SD)为78.9%;中位生存时间(MST)为10.1个月。QOL评分由治疗前平均34.5分提高到49.1分,KPS评分由治疗前平均78.6分提高到88.1分。主要毒副反应为骨髓抑制,白细胞下降的发生率为82.5%,其中Ⅲ～Ⅳ度占15.0%;血小板减少的发生率30.0%,其中Ⅲ～Ⅳ度占7.5%。结论:由HCPT联合CBP组成HC方案治疗老年性晚期NSCLC的疗效确切,能够改善患者的生活质量,毒副反应较轻,易于耐受,并且费用低廉,值得临床上进一步研究试用。
Objective：To observe the recent efficacy and toxicity of hydroxy camptothecin（HCPT） plusing carboplatin（CBP） for the senile patients with advanced non - small cell lung cancer（NSCLC）. Methods：The 40 patients （ ≥70years old ） with advanced NSCLC of stage Ⅲ B-Ⅳwere treated with HCPT 6mg/m^2 d1 -d5 and CBP （AUC = 5 ） d1 , q21-28d. The efficacy and toxity were evaluated after two cycles according to WHO criteria. The QOL and KPS were evaluated. Results ：The objective response might be evaluated in 38 cases. There were 16 cases with PR, 14 SD and 8 PD. Thus overall response rate RR（ CR ＋ PR） was 42. 1%. DCR（ CR ＋ PR ＋ SD） was 78. 9%. Median survival time （MST） was 10. 1 months. QOL increased from 34. 5 points to 49. 1 and KPS from 78. 6 to 88. 1. The major toxic reaction was bone marrow depression. The occurrence of leucopenia was 82.5% including 15.0% patients with grade Ⅲ-Ⅳ leucopenia,while the occurrence of thrombocytopenia was 30. 0% including 7.5% cases with grade Ⅲ-Ⅳ thrombocytopenia. Conclusion：The regimen consisted of HCPT and carboplatin for senile advanced non - small cell lung cancer is an effective and less toxic approach. It can improve life quality obviously with a cheap expense, deserving deep clinical research.
出处
《临床肿瘤学杂志》
CAS
2007年第7期498-500,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
晚期
老年人
化学治疗
羟基喜树碱
卡铂
Advanced NSCLC
Senile
Chemotherapy
Hyolroxycamptothecin（HCPT）
Carboplatin（CBP）
